Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
Introduction Diabetic retinopathy (DR) is one of the most frequent microvascular
complications of diabetes that can lead to blindness. Laser treatment has been the gold …
complications of diabetes that can lead to blindness. Laser treatment has been the gold …
A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy
LQ Zhao, H Zhu, PQ Zhao, YQ Hu - British journal of ophthalmology, 2011 - bjo.bmj.com
Aims To examine possible benefits of intravitreal bevacizumab (IVB) pretreatment in
vitrectomy for severe diabetic retinopathy. Methods A comprehensive literature search was …
vitrectomy for severe diabetic retinopathy. Methods A comprehensive literature search was …
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
JA Wells, AR Glassman, AR Ayala… - The New England …, 2015 - europepmc.org
Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …
A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data …
R Rajendram, S Fraser-Bell, A Kaines… - Archives of …, 2012 - jamanetwork.com
Objective To report the 2-year outcomes of the BOLT study, a prospective randomized
controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic …
controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic …
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
Diabetic Retinopathy Clinical Research … - New England Journal …, 2015 - Mass Medical Soc
Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema
DV Do, U Schmidt-Erfurth, VH Gonzalez, CM Gordon… - Ophthalmology, 2011 - Elsevier
PURPOSE: To determine whether different doses and dosing regimens of intravitreal
vascular endothelial growth factor (VEGF) Trap-Eye are superior to focal/grid …
vascular endothelial growth factor (VEGF) Trap-Eye are superior to focal/grid …
Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema
MM Wessel, N Nair, GD Aaker, JR Ehrlich… - British Journal of …, 2012 - bjo.bmj.com
Purpose To determine the relationship between retinal ischaemia and the presence of
macular oedema (DMO) in patients with diabetic retinopathy (DR) using ultra-widefield …
macular oedema (DMO) in patients with diabetic retinopathy (DR) using ultra-widefield …
Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits
H Nomoto, F Shiraga, N Kuno, E Kimura… - … & visual science, 2009 - iovs.arvojournals.org
purpose. To investigate the pharmacokinetics of bevacizumab in rabbits for three different
routes of administrations: intravitreal injection, subconjunctival injection, and eye drops …
routes of administrations: intravitreal injection, subconjunctival injection, and eye drops …
Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans
Purpose: To compare the concentration of unbound bevacizumab in the anterior chamber of
patients with macular edema, who received a single intravitreal injection of two different …
patients with macular edema, who received a single intravitreal injection of two different …
Anti‐VEGF for the management of diabetic macular edema
FR Stefanini, E Badaró, P Falabella… - Journal of …, 2014 - Wiley Online Library
Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the
leading cause in the population between 20 and 60 years old. Among patients with DR …
leading cause in the population between 20 and 60 years old. Among patients with DR …